Skip to main content
Clinical Trials/2024-514349-13-00
2024-514349-13-00
Recruiting
Phase 3

A2B-trial Antibioprophylaxis for excision-graft surgery in burn patient : a multicenter randomized double-bling study

Assistance Publique Hopitaux De Paris10 sites in 1 country506 target enrollmentStarted: August 23, 2024Last updated:

Overview

Phase
Phase 3
Status
Recruiting
Enrollment
506
Locations
10
Primary Endpoint
Post-operative infection defined as Post-operative sepsis and/or surgical site infection, and/or autograft lysis requiring a new autograft within 7 days after surgery

Overview

Brief Summary

Evaluate the impact of systemic antibiotic prophylaxis on postoperative infections, sepsis and autograft lysis needing new skin autograft (within 7 days postoperatively) in burn patients.

Study Design

Allocation
Randomized
Primary Purpose
A2b-trial
Masking
Double (Investigator, Monitor, Carer, Subject)

Eligibility Criteria

Ages
18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Major patient over 18 years
  • Burned patients requiring at least one excision-graft surgery
  • burn TBSA between 5 and 40%
  • Signed informed consent or inclusion under the emergency provisions of the law (article L1122-1-2 of the CSP)

Exclusion Criteria

  • Proven severe allergy to cephalosporin or piperacilline-tazobactam or any other antibacterial agent of the penicillin class
  • known colonization of the burned area to be excised with tazocillin-resistant germ.
  • obese patient with BMI > 50 kg/m²
  • History of severe allergic reaction to any other beta-lactam (eg cephalosporins, monobactams or carbapenems).
  • Patient on antibiotic therapy at the time of surgery
  • Pregnant or breast-feeding patient
  • Patient not covered by the social security
  • Patient transferred from another burn Unit
  • Patient participant in investigational competitive medicinal product study on the primary endpoint
  • Patient with local or systemic signs of infection requiring systemic antimicrobial therapy

Outcomes

Primary Outcomes

Post-operative infection defined as Post-operative sepsis and/or surgical site infection, and/or autograft lysis requiring a new autograft within 7 days after surgery

Post-operative infection defined as Post-operative sepsis and/or surgical site infection, and/or autograft lysis requiring a new autograft within 7 days after surgery

Secondary Outcomes

  • - 90 days mortality
  • - Skin raft lysis requiring a new autograft procedure
  • - Post-operative pulmonary infection
  • - Number of days of hospitalization until complete healing (> 95% total burn surface area)
  • - Number of hospitalization days living without antibiotic therapy at D28 and D90
  • - Multiresistant bacteria (15) colonization of infection at D28 and D90

Investigators

Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

coordinating investigator

Scientific

Assistance Publique Hopitaux De Paris

Study Sites (10)

Loading locations...

Similar Trials